Last reviewed · How we verify
allopurinol sustained-release capsules
Allopurinol inhibits xanthine oxidase, the enzyme responsible for converting hypoxanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid levels.
Allopurinol inhibits xanthine oxidase, the enzyme responsible for converting hypoxanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid levels. Used for Gout prophylaxis and treatment, Hyperuricemia, Uric acid nephropathy prevention.
At a glance
| Generic name | allopurinol sustained-release capsules |
|---|---|
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Drug class | Xanthine oxidase inhibitor |
| Target | Xanthine oxidase |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Metabolic disorders |
| Phase | FDA-approved |
Mechanism of action
Allopurinol is a purine analog that competitively inhibits xanthine oxidase, a key enzyme in the final steps of purine metabolism. By blocking this enzyme, it decreases the production of uric acid from its precursors. The sustained-release formulation provides prolonged drug exposure, allowing for once-daily dosing and more stable uric acid suppression compared to immediate-release formulations.
Approved indications
- Gout prophylaxis and treatment
- Hyperuricemia
- Uric acid nephropathy prevention
- Tumor lysis syndrome prevention
Common side effects
- Rash
- Gastrointestinal upset (nausea, diarrhea)
- Elevated liver enzymes
- Hypersensitivity syndrome
- Gout flare (initial treatment)
Key clinical trials
- Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets (PHASE4)
- Allopurinol in Acute Coronary Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: